Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19144 | 1.00 | NCF1 (0.33) | NCF1CHRM1 | |
| SCHEMBL2741016 | 0.97 | — | — | |
| SCHEMBL10196624 | 0.97 | — | — | |
| SCHEMBL81182 | 0.97 | — | — | |
| SCHEMBL23468934 | 0.93 | KDM4E (0.35) | NCF1 | |
| Piperazine SCHEMBL28251647 | 0.85 | — | — | |
| SCHEMBL20161594 | 0.82 | — | — | |
| SCHEMBL15177476 | 0.81 | ATM (0.32) | CHRM1 | |
| SCHEMBL20161407 | 0.81 | ATM (0.32) | CHRM1 | |
| SCHEMBL20161477 | 0.81 | ATM (0.32) | CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003078-B2 | Targeted MR imaging agents | BARNES-JEWISH HOSPITAL (US) | 2011-08-23 | — | — | US | disclosed |
| US-7312327-B2 | Method of preparing nitrogen macrocycles | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2007-12-25 | — | — | US | disclosed |
| US-20070237721-A1 | TARGETED MR IMAGING AGENTS | KEREOS, INC. | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070237721-A1 | TARGETED MR IMAGING AGENTS | TSPO, ARNT, RXFP4 | NCF1 3307/4885CHRM1 1976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.